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Abstract: The present review is aimed at analysing the current evidence concerning the potential
modulation of obesity and/or diet in adipose tissue ACE2. Additionally, the potential implications
of these effects on COVID-19 are also addressed. The results published show that diet and obesity
are two factors that effectively influence the expression of Ace2 gene in adipose tissue. However, the
shifts in this gene do not always occur in the same direction, nor with the same intensity. Additionally,
there is no consensus regarding the implications of increased adipose tissue ACE2 expression in
health. Thus, while in some studies a protective role is attributed to ACE2 overexpression, other
studies suggest otherwise. Similarly, there is much debate regarding the role played by ACE2 in
COVID-19 in terms of degree of infection and disease outcomes. The greater risk of infection that
may hypothetically derive from enhanced ACE2 expression is not clear since the functionality of the
enzyme seems to be as important as the abundance. Thus, the greater abundance of ACE2 in adipose
tissue of obese subjects may be counterbalanced by its lower activation. In addition, a protective role
of ACE2 overexpression has also been suggested, associated with the increase in anti-inflammatory
factors that it may produce.
Keywords: SARS-CoV-2 infection; COVID-19; adipose tissue; obesity; diet composition; caloric
restriction; ACE2; renin–angiotensin system
1. Introduction
The COVID-19 pandemic that started in December 2019 in Wuhan (Hubei province,
China) has caused a global health-crisis, resulting in more than 160 million confirmed cases
and causing almost 3.5 million deaths worldwide by May 2021 [1]. The disease is produced
by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped,
positive-sense, single-stranded RNA virus sharing 50% and 79% of its genome sequence
with the Middle East respiratory syndrome coronavirus (MERS-CoV) and the SARS-CoV,
respectively [2]. It is estimated that 80% of the cases are asymptomatic or develop mild
symptoms, while 10–20% of the cases develop severe symptoms (including pneumonia)
and a further 5% of the cases develop acute respiratory syndrome distress, multi organ
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failure or septic shock [3,4]. As far as SARS-CoV-2 transmission is concerned, aerosols have
been identified to play a major role in human-to-human transmission [5].
Angiotensin-converting enzyme 2 (ACE2) has been identified as a major player in
human SARS-CoV-2 infection (Figure 1). In this regard, the viral spike protein of SARS-CoV-
2 interacts with ACE2 extracellular domains, facilitating the entry of the virus into alveolar
cells [6], a process in which the transmembrane serine protease 2 (TMPRSS2) protein is
also involved [7]. Indeed, the higher binding affinity of SARS-CoV-2 towards ACE2 is
considered among the factors leading to the rapid spread of the disease worldwide [8].
Once the virus enters into the cell, the expression of ACE2 is dramatically decreased
in pulmonary tissue, resulting in higher circulating angiotensin II levels that in turn
can aggravate lung tissue inflammation [9]. Moreover, the cell damage derived from
this enhanced pulmonary tissue inflammation induces macrophage recruitment, which
is known to trigger the so-called “cytokine storm”, commonly resulting in further cell-
deterioration and inflammation [10].
Figure 1. Summarised schematic representation of the SARS-CoV-2 viral infection process and
derived outcomes in pulmonary tissue. ACE2: angiotensin-converting enzyme 2, Ang II: angiotensin
II, TMPRSS2: transmembrane serine protease.
ACE2 is part of the renin–angiotensin system (RAS), which in turn is a major regulator
of electrolyte balance and blood pressure [11]. Under physiological conditions, the an-
giotensinogen (AGT) produced in the liver undergoes renin-mediated cleavage, resulting
in angiotensin I. Then, the angiotensin-converting enzyme (ACE), which is located in the
pulmonary vasculature endothelium, converts angiotensin I in angiotensin II (Figure 2).
Subsequently, angiotensin II binds to two angiotensin receptors (AT), angiotensin receptor
1 (AT1) being the receptor mediating the majority of the angiotensin II physiological effects,
such as vasoconstriction, growth stimulation or water and salt retention. These receptors
are widely distributed in various organs and tissues, such as heart, liver, lungs or blood
vessels. By contrast, angiotensin receptor 2 (AT2) exerts vasodilatory effects and inhibits
cell growth and differentiation once having bound angiotensin II, somehow counterbal-
ancing the effects of AT1 [11]. In addition, angiotensin I and II have the ability to produce
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angiotensin 1-9 and angiotensin 1-7. In this regard, angiotensin I is cleaved by ACE2 to
produce angiotensin 1-9, which binds AT2, triggering blood pressure reduction through
increased natriuresis and nitric oxide (NO) production. With regard to angiotensin II, it
can be cleaved by ACE2 to produce angiotensin 1-7, which binds Mas receptor (MasR)
and reduces blood pressure. Interestingly, angiotensin 1-7 can also be produced from
angiotensin I, a process that is mediated by neprylsin (NEP) [12].
Figure 2. Schematic representation of the renin–angiotensin system. ACE: angiotensin-converting
enzyme, ACE2: angiotensin-converting enzyme 2, AT1: angiotensin receptor 1, AT2: angiotensin
receptor 2, MasR: Mas receptor, NEP: neprilysin, NO: nitric oxide.
The ACE/Ang-II/AT1 receptor axis and AT2 receptor are known as the “harmful” or
classical arm of the RAS and the “protective” arm of the RAS, respectively. Up-regulation
of Ang II/AT1R-mediated signalling has been identified in pulmonary diseases [13]. In-
deed, the activation of the ACE/Ang II/AT1R cascade is associated with increased risk
of pneumonia and worse prognosis [14]. After SARS-CoV-2 infection, an imbalance in
both arms of the RAS system takes place. Thus, COVID-19 shares this pathophysiological
pathway with pulmonary hypertension and pulmonary fibrosis, both commonly seen
in chronic lung diseases such as chronic obstructive lung disease, and with acute lung
diseases, especially acute respiratory distress syndrome [15]. In the matter of the damage
produced by COVID-19, data obtained in several studies have demonstrated that once a
subject is infected, an uncontrolled systemic inflammatory response takes place, which is
triggered by the immune system [13]. This inflammatory response mainly affects the lungs,
especially harming the alveolar epithelium and pulmonary interstitial arteriolar walls,
which results in reduced lung capacity and function impairment [13]. Regarding inflamma-
tion, it has been demonstrated that ACE2 attenuates this process, protecting against lung
injury of acute respiratory distress syndrome and restores the balance in RAS [15]. Thus,
appropriate ACE2 activity might be decisive in preventing immune-induced damage and
ensuring tissue repair [16]. Taking all that into account, the scientific community is testing
ACE inhibitors, ACE-2 agonists and Mas or AT2 receptor activators, among others [17,18],
in hospitalised patients. It would also be of interest to study the potential therapeutic
possibilities of ACE2 metabolites, including angiotensin (1-7), des-Arg (9)-bradykinin,
apelin and dynorphin [15].
COVID-19 derived impairments are not limited to pulmonary tissue, and this is
mainly due to the specific characteristics of SARS-CoV-2 spike protein, which enables the
virus to provoke multi-organ failure [19,20]. It is noteworthy that different studies have
demonstrated the tendency amongst obese subjects to develop a more severe COVID-19
infection, the body mass index (BMI) of a subject being related to the risk of admission
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in intensive care units (ICU) or even death [21]. In this regard, it has been suggested
that the acute inflammation triggered by COVID-19 is amplified in obese subjects due
to the subjacent chronic low-grade inflammation that is commonly associated to this
disease, leading to a more severe disease phenotype [22]. It has been proposed that this
effect is driven by the pro-inflammatory cytokine dysregulation underlying the obesity-
derived low-grade inflammation, which may overreact to SARS-CoV-2 infection [22,23].
The aforementioned effects of obesity on COVID-19 seem to be independent from further
health alterations related to this disease, such as diabetes or cardiovascular diseases [24],
which in turn highlights the connection between excessive adipose tissue accumulation
and COVID-19 development [25].
Besides the apparent higher risk of obese subjects to develop a more severe COVID-19
infection, it has been suggested that obesity may also lead to a higher risk of SARS-CoV-2
infection. In this regard, it must be noted that in addition to the lungs, ACE2 is also
expressed in white adipose tissue, where it shows a higher expression in comparison to that
found in pulmonary tissue [26]. Moreover, studies conducted in animal models (rodents)
have demonstrated that the adipose tissue ACE2 can be up-regulated in diet-induced
obesity (high-fat feeding) [27], which converts adipose tissue in a potential target and a
reservoir for COVID-19 [23].
At this point, it would be plausible to assume that obese subjects may be more prone to
get infected by SARS-CoV-2, and to develop a more severe COVID-19 infection. However,
the relationship between both diseases has become more complex. Even though obese
subjects are more likely to develop COVID-19 pneumonia, their mortality rate has been
reported to be lower than that of non-obese subjects [23]. Similar observations were
also described regarding ICU admissions, where obesity was related to the frequency of
admissions, but not with hospital stay length or mortality rate [28]. Additionally, there is
no consensus to date in regard to whether higher ACE2 may result in a negative (higher
amount of viral infection targets) or a positive (regulation of RAS system) effect in relation
to the SARS-CoV-2 infection [29,30].
In this scenario, the aim of the present review article is to analyse the current evidence
with reference to the potential modulation that obesity and/or diet may exert in adipose
tissue ACE2 expression. Additionally, the potential implications of ACE2 expression and
modulation in COVID-19 are also addressed.
2. Influence of Different Dietary Patterns and Weight-Loss Strategies in Adipose
Tissue ACE2 Levels. Evidence from Preclinical Studies
A number of studies have addressed the relationship between different feeding pat-
terns in adipose tissue renin–angiotensin system (RAS) components, due to the suggested
link between the latter and metabolism regulation, as well as the development of inflam-
matory and cardiovascular diseases [31,32].
2.1. Preclinical Studies Carried Out in Dietary Rodent Models
2.1.1. Dietary Composition
Several preclinical studies have been carried out to analyse the effects of dietary com-
position on RAS components (Table 1). One such study was conducted by Gupte et al. [27],
in which the authors aimed at investigating whether ACE2 expression in adipose tissue
could be regulated by high-fat diet feeding. For this purpose, male C57BL/6 mice were fed
with a low-fat diet (LFD) or a high-fat diet (HFD) (10 and 60% of energy as fat, respectively)
for one week or four months. The results revealed that after four months of HFD feeding,
the circulating levels of angiotensin peptides I, II and IV were significantly boosted. By
contrast, this effect was not reported after a week of feeding. Moreover, the authors ob-
served that HFD feeding not only induced a significant increase in body and epididymal
adipose tissue weight, but also enhanced Agt mRNA levels in this adipose depot. Indeed,
a significant build-up in this marker was also observed in mice fed with either the HFD
for a week or for four months. In addition, the authors also found that, compared to their
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LFD-fed counterparts, Ace2 mRNA levels were significantly increased in epididymal and
subcutaneous adipose tissues of mice fed with the HFD for a week or for four months.
With regards to the ACE2 protein expression, it was significantly increased in epididymal
adipose tissue of mice fed with the HFD compared to the LFD-fed animals after a week,
while the opposite was observed (a significant decrease in HFD-fed mice) after four months.
Remarkably, ACE2 activity was also augmented in these same adipose depots after a week
of HFD diet feeding, whereas no such differences were appreciated in none of the studied
adipose depots after maintaining the animals for four months on this same diet. Finally,
the authors also studied desintegrin and metalloproteinase domain 17 (Adam17) mRNA
levels in epididymal adipose tissue, which is known to cleavage ACE2 from membranes.
Results revealed that after four months of HFD feeding, the gene expression of Adam17
was significantly increased in comparison to animals fed with the LFD.
The authors concluded that both short- and long-term HFD feeding influence adipose
tissue ACE2 expression, although differently. Thus, while under a short-term HFD feeding,
adipose tissue ACE2 gene and protein expressions as well as enzymatic activity were
increased. In addition, under long-term HFD feeding, the upsurge in ACE2 gene expression
was not accompanied by neither greater protein expression nor enzymatic activity. On the
contrary, ACE2 protein expression was decreased.
The same group [33] further hypothesized that differential tissue-specific ACE2 reg-
ulation and shift in angiotensin II/(1-7) balance may differently exert an influence over
obesity-related hypertension development in male and female mice. To prove such a
hypothesis, male and female C57BL/6 mice were fed with a LFD or a HFD (10 or 60% of
energy as fat, respectively) for four months. Once the experimental period was completed,
the authors found significant body weight and fat mass growth in mice of both sexes
that had been fed with the HFD, results that differed from those found in their LFD-fed
counterparts. When analysing the plasma angiotensin II levels, the authors did not find
sex differences between animals fed with the same diets. By contrast, and compared with
their LFD-fed counterparts, a significant increase in this parameter was found in males
fed with the HFD. Concerning plasma angiotensin (1-7) levels, and compared to males
receiving the same diet, a significant reduction was found in this parameter in females
fed with the LFD, while no differences were found between HFD-fed males and females.
Interestingly, significantly lower plasma angiotensin (1-7) levels were found in males fed
the HFD when compared to the LFD-fed males, whereas the opposite was appreciated
in females. Finally, no changes in adipose tissue ACE2 activity were reported amongst
the male mice. Contrarily, the females fed with the HFD showed a greater activation than
those in the LFD. Moreover, the LFD-fed female mice showed a significant reduction in
ACE2 activity when compared to the males fed with the same diet.
Based on the results obtained, the authors concluded that a sexual dimorphism exists
in the diet-induced obesity-mediated angiotensin II/(1-7) balance. Thus, in males, the HFD
feeding shifts the balance towards Ang II/AT1R stimulation and plasma angiotensin (1-7)
suppression, whereas in females, the same dietary pattern enhances plasma angiotensin
(1-7) levels.
In the study published by Pinho et al. [34], male FVB/N mice were fed: a diet that
followed the macronutrient recommendations for mature rodents (AIN-93M); a standard
with a lower carbohydrate content than the AIN-93 M diet; a high-glucose diet; a high-
protein diet; or a high-lipid diet for two months. At the end of the experimental period,
a lower body weight was found in the animals fed with the high-glucose diet compared
to those receiving the AIN-93M, the high-protein or the high-lipid diets. Retroperitoneal
adipose tissue weight remained unchanged, whereas compared to the group fed the
standard diet, increased epididymal adipose tissue weight was found in the groups fed
with the AIN-93M and high-protein diets, although not in those fed with the high-glucose
or the high-lipid diets. Moreover, reduced blood triglyceride levels were also observed
in the high-lipid diet-fed group when compared to the AIN-93M, high-protein and high-
glucose-diet fed animals. The authors also studied the gene expression of different RAS
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components in epididymal adipose tissue. In this regard, the Ace mRNA levels found in the
group fed with the high-lipid diet was significantly higher than that found in the groups
fed with the standard or AIN-93M diets. By contrast, a significant reduction in Ace2 gene
expression was reported in these animals. No differences among the other groups were
found. This result clearly differs from that obtained by Gupte et al. (2008) whose mice
were fed with a HFD for four months. No changes were observed concerning renin and
Agt gene expression among the experimental groups.
Based on what the results yielded, the authors concluded that high-lipid feeding mod-
ulates the expression of RAS components in adipose tissue, and it may therefore participate
in obesity-related health alterations. In addition, the reduction in ACE2 produced by this
dietary pattern would reduce the benefits associated with this enzyme, which is known to
counterbalance the RAS action.
Other studies have been conducted using rats of different strains (instead of mice) as
experimental models. Among them, Zhang et al. [35] carried out a study with male Sprague–
Dawley rats fed with a standard chow diet or a HFD (mainly fat from lard) for six months.
At the end of the experimental period, as expected, the body weight was greater in rats fed
with the HFD. Surprisingly, the weight of the adipose tissue was not determined. Serum
glucose, insulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride and free
fatty acid levels were also higher in rats fed with the HFD. In epididymal adipose tissue,
ACE2 gene and protein expression were augmented in animals fed with the deleterious diet.
In the experiment published by Coelho et al. [36] male Wistar rats were fed with a
standard chow diet and received tap water or water containing 20% sucrose solution for a
month in order to produce a model of metabolic syndrome with high plasma angiotensin
II levels. At the end of the experimental period, the authors found enhanced plasma
levels of insulin, triglycerides, leptin, angiotensin I and angiotensin II, as well as increased
plasma renin and ACE enzyme activities. Moreover, epididymal adipose tissue weight
was significantly increased in the sucrose-fed animals, as it was the de novo fatty acid
synthesis. A significant boost in angiotensin I, II and (1-7) levels in the epididymal adipose
tissue was also observed. By contrast, no differences in Ace mRNA levels were found.
ACE protein expression and activity were higher in rats receiving sucrose, although the
protein expression and the activity of ACE2 were decreased. Agt gene expression was
also decreased in the sucrose fed animals. In conclusion, even though At1 and At2 gene
expression remained unchanged, their protein expression was significantly increased in the
sucrose fed animals. Based on these results, the authors determined that sucrose intake not
only augmented epididymal adipose tissue weight and de novo fatty acid synthesis in rats,
but also regulated the ACE/ACE2 balance towards a vasodilator/antiproliferative effect.
Table 1. Selected preclinical studies addressing the influence of different dietary patterns and weight-loss strategies on
adipose tissue renin–angiotensin system modulation.
Reference Sample Experimental Design Observations on RAS
Gupte et al., 2008 [27] Male C57BL/6 mice(8-week-old)
Mice fed with a LFD or a HFD (10
or 60% of energy as fat) for 1 week
or 4 months.
↑ circulating levels of angiotensin
peptides I, II and IV were found
after 4 months of HFD feeding.
↑ gene expression of
angiotensinogen (epididymal AT)
and Ace2 (epididymal and
subcutaneous AT) in HFD fed
mice after 1 week or 4 months.
↑ ACE2 protein expression in
epididymal AT after 1 week of
HFD feeding.
↓ ACE2 protein expression in
epididymal AT after 4 months of
HFD feeding.
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Table 1. Cont.
Reference Sample Experimental Design Observations on RAS
Coelho 2010 [36] Male Wistar rats
Rats fed with a standard diet for
1 months. A group of rats
received sucrose in drinking
water (20% solution).
↑ plasma angiotensin I and II
levels in sucrose fed animals.
↑ plasma renin and ACE enzyme
activities in sucrose fed animals.
↑ angiotensin I, II and (1-7) levels
in epididymal AT of sucrose fed
rats.
↓ protein expression of ACE2 in
epididymal AT of rats receiving
sucrose.
↑ ACE protein expression and
activity in epididymal AT of rats
receiving sucrose.
↓ Agt gene expression in
epididymal AT of rats receiving
sucrose.
↑ AT1 and AT2 protein expression
in epididymal AT of sucrose fed
rats.
Gupte et al., 2012 [33] Male and female C57BL/6 mice(8-week-old)
Mice fed with a LFD or a HFD (10
or 60% of energy as fat) for
4 months.
↑ plasma angiotensin II levels in
male mice fed the HFD compared
to LFD-fed counterparts.
↓ plasma angiotensin (1-7) levels
in LFD fed females compared to
HFD fed males.
↓ plasma angiotensin (1-7) levels
in HFD fed males compared to
LFD fed males.
↑ plasma angiotensin (1-7) levels
in HFD fed females compared to
LFD fed males.
↑ AT ACE2 activity in HFD-fed
males and females compared with
LFD fed males.
Pinho 2013 [34] Male FVB/N mice(8-week-old)
Mice fed with a STD, an AIN-93M,
a HG, a HP or a HL diet for
2 months.
↑ Ace gene expression in the
epididymal AT of mice fed the HL
diet compared to the groups fed
with the STD and AIN-93M diets.
↓ Ace2 gene expression in
epididymal AT of mice fed the HL
diet compared to the animals fed
the AIN-93M diet.
Zhang et al., 2014 [35] Male Sprague-Dawley rats(8-week-old)
Rats fed with a STD or HFD
(mainly lard) for 6 months
↑ Ace2 gene and protein
expressions in epididymal AT in
HFD-fed rats.
De Almeida Pinheiro 2017 [37] Male Swiss mice(4-week-old)
Mice fed with a STD or a HFD
(61% of energy as fat) for
2 months.
Animals fed with the two diets
had free access to food or were
submitted to 20, 40 or 60% of food
restriction.
↑ At1 gene expression in ad
libitum HFD-fed mice compared
to STD-fed controls.
↓ Agt and Ace gene expression in
STD-fed animals submitted to
energy restriction compared to ad
libitum STD-fed counterparts.
↓ Ace gene expression in HFD-fed
animals submitted to energy
restriction compared to ad libitum
HFD-fed counterparts.
Oliveira Andrade et al., 2014 [38] Male FVB/N mice(4-week-old)
Mice fed with a STD or a HFD (11
or 61% of energy as fat) for
2 months.
An additional group of animals
fed with the HFD received
100 µg/kg bw/day of angiotensin
(1-7).
↓ Ace gene expression in
epididymal AT of mice fed the
HFD compared to mice fed the
STD diet.
↓ Ace and Agt, and ↑ Ace2 gene
expression in the epididymal AT
of mice fed the HFD and treated
with angiotensin (1-7), compared
to the non-treated animals.
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Table 1. Cont.
Reference Sample Experimental Design Observations on RAS
Crespo et al., 2017 [39] Male Wistar rats(8-week-old)
Rats fed with a STD or a HFD (8
and 61% of energy as fat,
respectively) for 2 months.
Animals on each diet underwent
L or SG.
After surgical intervention,
animals were fed the same diets
for 1 additional month.
↓ Gene expression of Agt in
periepididymal AT in STD and
HFD fed rats with SG compared
to animals with L fed the STD and
HFD.
↓ Ace gene expression in
periepididymal AT in STD- and
HFD-fed rats with SG compared
to animals with L fed the HFD.
↑ Ace2 gene expression in
periepididymal AT in HFD fed
rats with SG compared to animals
with L fed standard diet.
2.1.2. Energy Restriction
De Almeida Pinheiro et al. [37] studied the RAS in the adipose tissue of mice under
different dietary patterns. For that purpose, male Swiss mice were distributed into eight
experimental groups fed as follows: standard diet (66% carbohydrate, 23% protein and
11% fat, 3.95 kcal per g of diet) ad libitum; standard diet with a 20% of energy restriction;
standard diet with a 40% of energy restriction; standard diet with a 60% of energy restriction;
HFD (24% carbohydrate, 15% protein and 61% of fat, 5.28 kcal per g of diet) ad libitum;
HFD with a 20% of energy restriction; HFD with a 40% of energy restriction; and HFD with
a 60% of energy restriction. The length of the experimental period was two months. Thus,
the authors not only studied the effects of HFD feeding on RAS, but also those of different
degrees of energy restriction. At the end of the experimental period, as expected, body
weight and epididymal, retroperitoneal and mesenteric adipose tissue weights, as well as
adipocyte surface area, were reduced in mice under caloric restriction when compared to
their respective controls. When groups fed ad libitum with the standard diet or the HFD
were compared, the previously mentioned parameters were higher in the group fed with
the HFD.
The expression of different genes involved in the RAS system and related to inflam-
mation were measured in the epidydimal adipose tissue. When standard diet and HFD fed
control groups were compared, Agt, Ace and Ace2 levels did not differ between them. By
contrast, gene expression of At1 was higher in mice fed with the obesogenic diet than in
mice fed with the standard diet. With regard to the effect of energy restriction, Ace2 gene
expression remained unchanged in mice fed with the restricted standard diets. Further-
more, Agt and Ace mRNA levels were reduced, with the exception of the highest restriction
(60%) that did not modify their levels. In mice fed with the obesogenic diet, Ace mRNA
levels decreased when the amount of food was limited, whereas Agt levels only decreased
with the restriction of 40%. No differences were observed among groups in Ace2 or At1
mRNA levels.
With reference to inflammation, gene expression of interleukin 6 (Il-6) and tumor necrosis
factor alpha (Tnfα) were higher in mice fed with the obesogenic diet than in mice fed with
the standard diet. Regarding energy restriction, mice fed with the 40% restricted diet
with a standard composition showed decreased mRNA levels of both Il-6 and Tnfα. When
mice were fed with a high fat diet, Il-6 gene expression was reduced under the caloric
restriction of 40% and Tnfα under caloric restriction of 20% and 40%. In summary, mild to
moderate restriction (mainly 40% of food restriction) improved inflammatory status and
RAS components more than a severe restriction did and, in general, a weight reduction
could exert beneficial effects on RAS system. Regarding Ace2 mRNA levels, it was neither
modified by the diet composition nor by the caloric restriction or body composition.
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2.1.3. Non-Dietary Treatments Focused on Body Fat Reduction
In other studies, the effects of non-dietary treatments that reduce adipose tissue mass
have been addressed (Figure 3). In this line, Oliveira-Andrade et al. [38] carried out a study
to investigate the potential anti-obesity mechanisms of action of angiotensin (1-7). To do so,
male FVB/N mice were fed with a standard or a HFD (11 and 61% of energy as fat) for two
months. An additional group fed with the HFD received 100 µg/kg bw/day of angiotensin
(1-7). The authors did not report any changes in food intake or body weight among the
three groups. Epididymal, retroperitoneal and mesenteric adipose tissue weight was higher
in mice fed with the HFD. By contrast, significant reductions in the three depots were found
in the group fed with the HFD and treated with angiotensin (1-7) when compared with
the non-treated animals fed with the same diet. Moreover, serum biochemistry analysis
revealed that angiotensin (1-7) administration significantly reduced the increase in serum
triglyceride, total cholesterol, glucose and insulin levels induced by the HFD, as well as
improved glucose tolerance and insulin sensitivity tests.
Figure 3. Effects of energy restriction and other non-dietary treatments devoted to reducing body fat
on Ace2 gene expression in adipose tissue. NS: non-significant; ↑ increase.
When gene expression of different RAS components was studied in the epididymal
adipose tissue, the authors found that whereas Ace gene expression increased under the
high-fat feeding, Ace2 and Agt gene expression remained unchanged when compared to
mice fed with the standard diet. Angiotensin (1-7) administration significantly reduced
Ace and Agt mRNA levels when compared to the non-treated HFD fed mice. In addition,
a significant boost in Ace2 gene expression was appreciated in these animals too. The
authors also studied the protein expression of glucose metabolism markers in epididymal
adipose tissue. No differences in protein expression of phosphorylated AMP-activated
protein kinase (pAMPK), forkhead/wingedhelix O 1 (FOXO1) and glucose transporter 4
(GLUT4) were observed among animals fed with the standard diet or the high fat diet.
Peroxisome proliferator-activated receptor γ (PPARγ) protein expression was higher in
mice fed with the obesogenic diet. It has been observed that angiotensin (1-7) treatment
induced a significant increase in the protein expression of pAMPK, FOXO1 and GLUT4, as
well as a significant reduction of PPARγ protein expression when compared to mice fed
with the same diet but not treated with angiotensin (1-7).
Altogether, the results revealed that, in this experimental model, high-fat feeding,
which led to an increase in the size of epididymal adipose tissue, did not affect Ace2 gene
expression. Contrarily, oral angiotensin (1-7) administration, which reduced the size of this
adipose depot and improved the impairments induced by the HFD feeding in glucose and
lipid metabolism, did increase the expression of this gene.
In a recent study, Crespo et al. [39] explored the effect of sleeve gastrectomy (SG) on
the metabolic profile and on the expression of inflammatory markers and RAS components
in different tissues of rats featuring diet-induced obesity. Bearing this in mind, male Wistar
rats were fed with a standard or a HFD (8 or 61% of energy as fat, respectively) for two
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months. After this experimental period, animals receiving both diets were divided in two
groups that underwent a laparotomy or a SG. Following surgical intervention, animals
were maintained in the same experimental diets for an additional month.
After surgery, and compared to the animals fed with the same diets that had undergone
a laparotomy, a significant decrease in body weight and food intake (accompanied by
reductions in body adiposity, adipocyte area and the weights of epididymal, mesenteric
and retroperitoneal adipose tissues) were found among the animals that had been subjected
to SG. Moreover, the pre-surgery impairment of glucose tolerance and insulin resistance
produced by the HFD feeding were ameliorated in the animals that had SG. The authors
also studied the gene expression of proinflammatory cytokines and RAS components in
periepipidymal adipose tissue. The results revealed that the gene expression of Tnfα was
significantly lower in rats fed with both diets and subjected to SG, when compared to the
animals fed with the HFD that had undergone a laparotomy. Similar results were also
reported for Il-6 gene expression, although in this case the reduction reached significance
only in the group fed with the HFD and subjected to SG. In the case of RAS components, a
significant reduction in Agt gene expression was found among the animals fed with both
diets and that had undergone SG, in comparison to their respective laparotomiced controls.
In addition, and compared to the HFD fed laparotomiced animals, significant reductions in
Ace mRNA levels were also appreciated in standard and HFD rats that had SG performed.
By contrast, enhanced Ace2 gene expression was appreciated in animals subjected to SG
and fed with the HFD compared with their laparotomiced control counterparts and with
animals that were fed with the standard diet and that had undergone SG.
The authors concluded that the body weight-loss and adipose tissue reductions pro-
duced by SG were accompanied by the improvement of the metabolic profile of the animals.
Additionally, the authors also pointed out that the changes observed in adipose tissue
inflammatory markers and RAS components may play an important role in the metabolic
improvements derived from SG mediated weight-loss.
2.1.4. Conclusions
To put all the aforementioned studies concisely (Figure 4), it can be stated that the
composition of the diet, as well as the increase in adipose tissue mass, can effectively mod-
ulate the plasma levels and/or the adipose tissue expression/activity of RAS components,
although a general consensus has not been reached. Regarding the ACE2 protein, has
been related to SARS-CoV-2, Gupte et al. [27] and Olveira-Andrade et al. [38] observed an
increase in Ace2 gene expression in mice after four and two months of high-fat feeding,
respectively. Contrarily, Pinho et al. [34] observed a decline after two months. Moreover,
Alemida-Pinherio et al. [37] did not find significant differences after the two-month period.
Zhang et al. [31] reported an increased Ace2 gene expression in rats following a six-month
period of high-fat feeding. The discrepancy among these results remains unclear. The fact
that different species were used does not seem to justify such heterogeneous conclusions
since Gupte et al. [27] and Olveira-Andrade et al. [33] observed the same results in mice
than Zhang et al. [35] had observed in rats. Furthermore, the two-month experimental
period used in the trials does not support such heterogeneity neither because the studies
conducted by Oliveira et al. [38], Almeida et al. [37], and Pinho et al. [34] yielded divergent
results too. Lastly, the anatomic location of the adipose tissue does not seem a plausible ex-
planation for the conflicting findings since all the studies were carried out using epididymal
adipose tissue. Dietary patterns rich in carbohydrates have barely been analysed. Coelho
et al. [36] did not measure Ace2 gene expression in rats, but they observed a decrease in
ACE2 protein expression in rodents which received sucrose diluted in drinking water (20%
solution). By contrast, Pinho et al. [34] did not find significant differences after two months
of high-glucose feeding.
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Figure 4. Effects of diet composition on ACE2 gene and protein expression in adipose tissue. NS:
non-significant; ↑: increase; ↓: decrease.
In addition to the effect of diet composition, other dietary interventions such as energy
restriction have been studied. The reported data did not show any modification in Ace2
gene expression, either under standard feeding or under high-fat feeding. Nevertheless,
it is important to point out that this data comes from an isolated study and thus further
research is required to reach a solid conclusion. The influence on Ace2 of other non-dietary
treatments that lead to a reduction in adipose tissue weight such as administration of
angiotensin (1-7) or gastrectomy have also been reported. These have shown an increase in
Ace2 gene expression in adipose tissue [38,39]. Although a correlation analysis between
adipose tissue size and Ace2 expression has not been carried out in the aforementioned
studies, the reported data cannot be used to hypothesize about the potential relationship
between these two parameters.
2.2. Preclinical Studies Carried Out in Genetically Modified Rodent Models
Genetically modified rodent models have been used to address the potential rela-
tionship among ACE2, obesity and diet. Patel et al. [40] fed wild-type (WT) and ACE2
knockout (ACE2KO) male C57BL/6 mice with a standard diet (10% energy from fat) or a
HFD (45% energy from fat) from weaning to six months. In ACE2KO mice fed with the
HFD, a subcutaneous pump was placed to deliver Angiotensin (1-7) or saline (control)
for four weeks. At the end of the experimental period, the HFD feeding increased body
weight, fat content and epicardial adipose tissue to a similar level in both WT and ACE2KO
mice. However, no differences in these parameters were observed in mice fed with a stan-
dard diet. Angiotensin (1-7) administration completely reversed body weight gain, while
partially reversed the increment on body fat content. Fasting glucose was significantly
increased in mice fed with the obesogenic diet but to a higher level in the ACEKO group.
Intraperitoneal glucose tolerance test (IPGTT) area was only increased in ACE2KO mice
that had been fed with the HFD. No data regarding fasting plasma glucose levels was
provided in mice receiving Angiotensin (1-7), but a reduction in IPGTT area was observed.
In epicardial adipose tissue, adipocyte area was increased in HFD fed mice, and
this effect was reversed by Angiotensin (1-7) but without reaching the values found in
mice fed with the standard diet. Inflammatory markers were measured in this same
adipose tissue. Immunofluorescent staining showed an increase in CD11c+/F4/80+ and
CD206+/F4/80+ macrophage phenotypes in mice fed the obesogenic diet. The increase of
CD11c+/F4/80+ was greater in ACE2KO mice while in the case of CD206+/F4/80+ the
increase was lower. In this regard, it should be pointed out that F4/80 is a cell-surface
marker of macrophages, CD11c is a marker of pro-inflammatory phenotype of macrophages
and CD206 a marker of anti-inflammatory phenotype of macrophages. Taking that into
account, these results could be indicating that ACE2KO mice are more prone to diet induced
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inflammation. It bears mentioning that Angiotensin (1-7) administration restored the levels
of both macrophage ratios. In addition, different markers of inflammation and macrophage
infiltration were measured by RT-PCR. Monocyte chemoattractant protein 1 (Mcp1) expression
was higher in mice fed the HFD, being this increase even higher in ACE2KO mice. This
effect was completely reversed by Angiotensin (1-7) administration. Not only macrophage
infiltration, but also gene expression of pro-inflammatory cytokines Il-1β and Il-6 was
higher in mice fed the obesogenic diet being this effect again avoided by Angiotensin
(1-7) administration. TNFα protein levels and gene expression, as well as inducible nitric
oxide synthase (iNos), and anti-inflammatory Il-10 gene expression were only measured in
ACEKO mice. In this regard, their levels were higher in ACE2KO mice without Angiotensin
(1-7) administration than when this compound was administered or when compared to
the mice fed the standard diet. Summarizing, ACE2 can negatively regulate HFD induced
epicardial adipose tissue inflammation and Angiotensin (1-7) administration improves
the inflammation.
Inflammatory markers revealed that ACE2KO mice were more prone to diet-induced
inflammation than WT mice. The alterations induced by the high-fat feeding on these
biomarkers were reverted by Angiotensin (1-7) administration. In this study, the authors
found a novel role of ACE2 in obesity, where ACE2 negatively regulated obesity-induced
epicardial adipose tissue inflammation, cardiac insulin resistance, and alterations in cardiac
metabolism. Angiotensin 1-7 treatment improved these shifts. Consequently, the authors
concluded that enhancing ACE2 or Ang 1-7 action represented potential therapeutic op-
tions for obesity and its associated heart disease. The effect on epicardial adipose tissue
inflammation could be of interest in SARS-CoV-2 infection.
More recently, Shoemaker et al. [41] studied the effect of ACE2 in adipocytes. To do
so, a mouse model of ACE2 deficiency was generated in both male and female C57BL/6
mice. ACE2 deficient and non-deficient mice were fed with a HFD (60% kcal from fat) or
LFD (10% kcal from fat) for 16 weeks. At the end of the study, the body weight was greater
in males than in females (independently of the diet). Body weight was also found to be
increased in animals fed with the HFD than in mice fed with the LFD, without differences
between both genotypes. Females fed with the LFD had lower percentage of fat mass
than their male counterparts did. By contrast, female mice fed with the HFD had a higher
percentage of fat than males. In both females and males, the percentage of fat mass did
not vary in ACE2 deficient mice when compared to non-deficient mice, regardless of the
diet they had been fed with. In view of these results, the authors concluded that adipocyte
ACE2 does not seem to be protective in the development of obesity in female or male
mice. This conclusion is not in good accordance with that of the study carried out by
Shoemaker et al. [41].
3. Influence of Obesity and Diet in Adipose Tissue ACE2 Levels. Evidence from
Studies Conducted in Humans
After having analysed to which extent RAS components can be modulated by diet and
treatments devoted to reducing body fat in animal models, the next step is to address this
issue in humans. Although the data available in humans is scarce in comparison to that
obtained in animal models, some authors have investigated this topic. It must be noted
that, due to ethical reasons, and contrarily to what happens in animal studies, no study
conducted in humans was carried out where participants received high-fat or unbalanced
diets. Therefore, the influence of diet in adipose tissue ACE2 expression has been based on
the analysis of the outcomes found after weight-loss interventions.
As in rodents, it has been reported that the expression of ACE2 in human adipose
tissue is greater than that occurring in lung tissue [42]. Similarly, by using publicly available
subcutaneous adipose tissue transcriptomics datasets (GSE), it has been demonstrated
that ACE2 expression is also modulated by diet in humans [43]. In addition, according to
recently published data, it seems that interventions devoted to inducing weight-loss in
humans can also modulate ACE2 expression in white adipose tissue. Thus, an Ace2 gene
expression decrease has been observed in subcutaneous adipose tissue of overweight or
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obese subjects of both sexes (28–35 kg/m2 BMI) that underwent weight-loss (five weeks
following low-calorie diets). Additionally, it was also observed that this change in Ace2 ex-
pression was maintained in subjects whose body weight-loss was more stable [43]. Similar
results were found in a study in which overweight or obese subjects (BMI ≥ 27 kg/m2)
were first subjected to a multimodal 12-week weight-loss intervention (low energy diet,
nutritional counselling, physical activity and psychological support), and then maintained
for a 12-month weight-maintenance period (with or without nutritional counselling) [44].
In this study, pre-intervention data revealed that, compared with healthy obese subjects,
subcutaneous adipose tissue Ace2 gene expression was lower in insulin resistant subjects.
The weight loss induced by the multimodal intervention (at least 8% of body weight)
significantly decreased subcutaneous adipose tissue Ace2 gene expression. Remarkably,
the authors found that the post-intervention improvement in insulin sensitivity was less
marked in those subjects featuring a stronger reduction in adipose tissue Ace2 gene expres-
sion [44].
Besides dietary interventions, bariatric surgery, such as Roux-en-Y gastric bypass
(RYGB), represents an additional effective intervention tool to reduce adipose tissue volume.
Therefore, RYGB is currently considered as a potential strategy to reduce COVID-19 risk
of infection, especially in patients suffering from severe obesity [45]. Indeed, analysis on
publicly available transcriptomic datasets (GSE59034) of subcutaneous white adipose tissue
(sWAT) biopsies from 16 women before and 2 years after RYGB revealed that ACE2 gene
expression is down-regulated by RYGB in this tissue. It is worth noting that the Ace2 gene
expression in these patients resulted even lower than that found in subcutaneous adipose
tissue of subjects that had never been obese [45].
Altogether, the results of the aforementioned studies show that a reduction in adipose
tissue weight is paralleled by a decrease in Ace2 gene expression in this tissue. Never-
theless, there are also studies that have found no Ace2 gene modulation in patients under
different nutritional status. De Almeida Pinheiro et al. [37] conducted a study in which the
gene expression of several inflammatory markers and RAS components were measured in
adipose tissue of eutrophic, obese and malnourished subjects. The authors found that com-
pared with eutrophic subjects, gene expression of Il-6, Tnfα, Agt and Ace in visceral adipose
tissue were significantly increased in obese and malnourished participants. According to
the results previously described, increased Ace2 gene expression would be expected in
obese subjects. However, no differences among the three groups were found.
Moreover, a recent meta-analysis that compared data of Ace2 gene expression in
subcutaneous adipose tissue of participants in three cohorts (TwinsUK, METSIM and
FUSION) that differed in geographic, demographic and phenotypic characteristics, reported
that Ace2 gene expression was negatively associated with BMI [46]. Indeed, the authors
not only found that adipose tissue Ace2 gene expression was lower in obese subjects than
in normal-weight subjects, but they also observed that this parameter was even lower in
those subjects featuring type 2 diabetes. Interestingly, the authors focused their attention
both on the amount of adipose tissue of the subjects and on the cell type present in it. In
this regard, the presence of microvascular endothelial cells (MVEC) was related to a higher
Ace2 gene expression, despite the fact that this expression was decreased when a greater
macrophage level was present in the adipose tissue [46].
Ultimately, the data reported to date does not allow to draw a clear conclusion con-
cerning the relationship between adipose tissue size and Ace2 gene expression in this tissue
and thus to link this relationship with an increased risk of being infected by SARS-CoV2
virus and the poor prognosis of COVID-19 amongst obese subjects.
In addition to the effect that dietary and non-dietary interventions devoted to reduc-
ing adipose tissue size can have on Ace2 gene expression, some authors have focused
their attention on the potential role of seaweeds, since in Japan and South Korea, two
countries where seaweeds are commonly included in the diet, the number of deaths per
100,000 inhabitants have been clearly lower than in other countries were seaweeds do not
take part of the usual dietary patterns [47]. Tanama (2020) has reported that seaweeds
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components appear to counteract the dominance of the ACE/Ang II/ATR1 axis in pa-
tients with COVID-19. Thus, the peptides in edible seaweeds might function as dietary
ACE inhibitors, leading to a protective effect against COVID-19 by reducing the degree of
ACE/Ang II/ATR1 axis dominance [48].
4. Influence of Obesity and ACE2 in COVID-19. beyond ACE2 Expression
As already mentioned in this review, the current knowledge on the mechanisms
involved in SARS-CoV-2 infection points towards obesity as a risk factor for a greater viral
entry. This assumption is based on the adipose tissue ACE2 expression and the abundance
of such tissue in obese individuals. Additionally, a recent study has revealed that Ace2
gene expression is enhanced in lung epithelial cells of obese subjects [43]. Moreover, in
the same study, increased gene expression of Tmprss2, a serine protease known to be used
by SARS-CoV-2 to bind S protein, was also found in the same cell line in obese subjects.
These findings led to investigations that sought tissues that express ACE2 in order to find
potential targets for viral infection. However, much care is needed when considering
tissues with higher ACE2 expression as the main players in viral infection. In this line, it
must be noted that whereas ACE2 expression in pulmonary tissue is lower than in other
tissues (such as adipose tissue), the viral load usually found in the lungs is high. Similar
observations have also been made with regards to the gastrointestinal tract, where the
highest viral loads have been found in the colon, whereas the highest ACE2 expression
occurs in the small intestine. These observations led to the idea that it is also possible to
cause a productive SARS-CoV-2 infection with fewer ACE2 molecules [49]. Indeed, some
studies carried out years before the outbreak of the COVID-19 pandemic suggested that
ACE2 overexpression may actually exert a beneficial effect on lung inflammation [50].
With regard to the role of obesity in COVID-19, there is an overall consensus in
terms of the negative effects of this metabolic disease on the progression and outcomes
of the viral infection [51]. Interestingly, it has been proposed that the excess of adipose
tissue, characteristic of obesity, may play a dual role in COVID-19. Thus, the reduction in
ACE2 that occurs once SARS-CoV-2 enters the cell, results in increased levels of circulating
angiotensin II, producing a pro-inflammatory response that may enhance lung tissue
inflammation. By contrast, the increased ACE2 expression that has been proposed to
occur in adipose tissue of obese subjects [52–54] may also result in higher angiotensin
(1-7) levels, which is known to exert anti-inflammatory and antioxidant effects, and thus
might help alleviating SARS-CoV-2 infection induced damage [9]. Moreover, it has been
proposed that in terms of a greater risk for a SARS-CoV-2 infection, the activation level of
ACE2 is as important as its expression. In this regard, metabolic disorders characterised
by inflammation (such as obesity) may result in greater ACE2 shedding from adipose
tissue. Since in adulthood, adipose tissue expansion occurs through adipocyte hypertrophy,
a process that is related to greater adipose tissue inflammation [55], it is plausible to
suggest that the adipose tissue inflammation that occurs in obesity could also reduce
ACE2 functionality in this tissue, and thus somehow protect the host from a SARS-CoV-2
infection [9].
In addition, it has also been observed that soluble ACE2 may contribute to COVID-19
susceptibility, although its significance remains uncertain. In this sense, subjects with
obesity and patients with COVID-19 have higher serum ACE2 levels [56–59]. The increased
soluble ACE2 levels in COVID-19 patients may result from the cellular lysis that occurs
when a severe infection takes place. Increased plasma levels of this protein seem to be
associated with a higher severity and worse outcome of the disease [60]. By contrast,
in other tissues such as lung or heart this increase could exert protective effects against
the severity of the infection in part due to its anti-inflammatory and anti-hypertensive
effect [61]. Nevertheless, serum ACE2 proceed from different tissues and thus it is not
feasible to know the extent to which adipose tissue, or other tissues, contribute to ACE2
release into blood.
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Sex is another factor to take into account in COVID-19 infection and development
equation [9]. For instance, the greater visceral adipose tissue accumulation found in the
upper body that is common in men has been widely linked to adipose tissue inflammation
and further metabolic impairments [55]. Thus, it has been hypothesized that this specific
fat accumulation pattern may result in decreased adipose tissue surface ACE2 expression,
which in turn could reduce the risk of a viral infection. Indeed, the higher circulating ACE2
levels that are usually found in men would corroborate this assumption [9]. Moreover,
due to hormonal (oestrogens upregulate ACE2 expression) and genetic factors (ACE2 is
located in the X chromosome), ACE2 expression is greater in women, which may account
for lower COVID-19 death rates than in men [62]. Additionally, lifestyle factors (such as
tobacco smoking), as well as immune system functioning may provide women with more
protection against a viral infection [62,63].
5. Conclusions
Regarding the first aim of the present review article, to analyse the current evidence
with reference to the potential modulation that diet and obesity may exert in adipose
tissue ACE2 expression, scientific evidence clearly shows that diet composition, mainly the
amount of fat, affects this parameter. Unfortunately, the results available to date have been
obtained in animal models and further studies are urgently needed to determine whether
the reported effects are also induced in human beings. On the other hand, in humans,
energy restriction leads to a reduction in Ace2 gene expression, but the effects of dietary
patterns other than restricted ones (i.e., Mediterranean diet and Western diet) should also be
addressed in order to better understand to which extent ACE2 can be modulated through
diet and to target dietary strategies with the aim of positively improving SARS-CoV
illness severity.
Concerning obesity, the data reported demonstrate that the severity of COVID-19, as
well as the outcomes of the disease, are worse in obese subjects. The results regarding
the potential implication of ACE2 expression and modulation in COVID-19, obtained in
preclinical studies or in studies carried out in humans, demonstrate that the shifts in ACE2
expression do not always occur in the same direction, nor with the same intensity.
With regard to the potential implications of ACE2 expression and modulation in
COVID-19, there is also much debate. The greater risk of infection that hypothetically
may derive from enhanced ACE2 expression is not clear, since the functionality of the
enzyme seems to be as important as its abundance. Thus, the greater affluence of ACE2
in adipose tissue of obese subjects may be counterbalanced by its lower activation. In
addition, a protective role of ACE2 overexpression has also been suggested, mainly due to
the potential increase in anti-inflammatory factors that it may produce. Indeed, the role
of ACE2 is still too vague and poorly characterized, and consequently this topic requires
further investigation since a great heterogeneity of results has been obtained within obese
subjects, especially regarding whether further metabolic disturbances besides obesity are
present or not. Nevertheless, its involvement in the action of the virus seems evident.
Finally, it is important to highlight that the number of studies carried out in hu-
mans are very scarce so far and the results obtained in animal models cannot be easily
extrapolated to human beings. This represents a clear limitation of the present review and
further reviews are needed in the near future, when more data will be available, to draw
stronger conclusions.
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